Global Blood Therapeutics, Inc. (NASDAQ:GBT) Files An 8-K Entry into a Material Definitive Agreement

Item1.01 Entry into a Material Definitive Agreement.

On February21, 2017, Global Blood Therapeutics,Inc. (the
Company) entered into an underwriting
agreement (the Underwriting Agreement)
with Cantor Fitzgerald Co., as representative of the several
underwriters (the Underwriters), to
issue and sell 5,102,041 shares of common stock of the Company
(Common Stock) in an underwritten
public offering to a Registration Statement on FormS-3 (File
No.333-214088) and a related prospectus and prospectus
supplement, in each case filed with the Securities and Exchange
Commission (the Offering).The public
offering price was $24.50 per share of Common Stock.The Company
estimates that the gross proceeds from the Offering, before
deducting underwriting discounts and commissions and estimated
offering expenses payable by the Company, will be approximately
$125.0 million. The Offering is expected to close on February27,
2017, subject to customary closing conditions.

The Underwriting Agreement contains customary representations,
warranties, covenants and agreements by the Company, customary
conditions to closing, indemnification obligations of the Company
and the Underwriters, including for liabilities under the
Securities Act of 1933, as amended, other obligations of the
parties and termination provisions. The representations,
warranties and covenants contained in the Underwriting Agreement
were made only for purposes of such agreement and as of specific
dates, were solely for the benefit of the parties to such
agreement, and may be subject to limitations agreed upon by the
contracting parties.A copy of the Underwriting Agreement is filed
as Exhibit1.1 to this Current Report on Form8-K and is
incorporated herein by reference.The foregoing description of the
Underwriting Agreement is qualified in its entirety by reference
to such exhibit. A copy of the legal opinion as to the legality
of the shares of Common Stock to be issued and sold in the
Offering is filed as Exhibit5.1 to this Current Report on
Form8-K.

Item8.01Other Events.

On February21, 2017, the Company issued a press release
announcing the commencement of the Offering.On February22, 2017,
the Company issued a press release announcing that it had priced
the Offering.Copies of the press releases are filed as
Exhibits99.1 and 99.2, respectively, to this Current Report on
Form8-K and are incorporated herein by reference.

Item9.01Financial Statements and Exhibits.

About Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. It is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD) and is evaluating GBT440 in SCD subjects in an ongoing Phase I/II clinical trial. SCD is a genetic disease marked by red blood cell (RBC) destruction and occluded blood flow and hypoxia, leading to anemia, stroke, multi-organ failure, severe pain crises, and shortened patient life span. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. It is also engaged in other research and development activities targeted towards hereditary angioedema (HAE).

Global Blood Therapeutics, Inc. (NASDAQ:GBT) Recent Trading Information

Global Blood Therapeutics, Inc. (NASDAQ:GBT) closed its last trading session down -4.10 at 24.40 with 8,234,106 shares trading hands.